{
    "nctId": "NCT02816164",
    "officialTitle": "A Multi Centre Study to Compare Administration Schedules of G-CSF (Filgrastim) for Primary Prophylaxis of Chemotherapy-Induced Febrile Neutropenia in Early Stage Breast Cancer (REaCT-G2)",
    "inclusionCriteria": "* Histologically confirmed primary breast cancer\n* Planned to start docetaxel component of FEC-D or AC-D, or first cycle of; dose-dense AC-T, TC, FEC-D or TAC chemotherapy\n* \u226519 years of age\n* Able to provide verbal consent\n* Must have minimum age of 19 Years",
    "exclusionCriteria": "* Contraindication to Filgrastim"
}